Study of Suv420h1/2 in liver cells
Part of Digestive system clinical trials.
This study looks at a protein called Suv420h1/2 in liver cells to understand its role in liver disease. It uses stored samples and data from people who already took part in related studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You already gave consent for genetic testing in a past study (SERENA, REASON, or MAFALDA).
- You agree to join this new study.
- You have one of the following: NAFLD with certain liver damage, or you are in the REASON study after a liver biopsy or surgery, or you had weight-loss surgery for obesity.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with fatty liver disease and common health issues like obesity, diabetes, high blood pressure, or abnormal cholesterol. It may help researchers understand how liver fat and heart/metabolism problems relate and how they affect health over time.
This study takes small samples of liver tissue to grow 3D 'mini livers' (organoids) in the lab. Researchers want to learn how non-alcoholic steatohepatitis (NASH), a serious fatty liver condition, starts and progresses, which could lead to better treatments.
This study collects health information from people with non-alcoholic fatty liver disease (NAFLD), a condition where fat builds up in the liver. It aims to learn more about the disease to improve future care.
This study collects health information and samples from people with non-alcoholic fatty liver disease to better understand the condition. It may help researchers find new ways to diagnose or treat this liver problem.
This study collects information about metabolic and unexplained (cryptogenic) liver disease and looks at “omics” tests, which are lab tests that measure patterns in blood or tissue to learn what drives the disease. It may help researchers better understand fatty liver and related serious complications, like liver scarring and liver cancer.
This study looks at your risk of developing liver cancer (hepatocellular carcinoma) if you have a liver condition such as NAFLD or a related disease. It aims to improve how doctors predict who might be at higher risk, so they can offer better monitoring and care.
Hear when a new NAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.